Who is sponsoring NCT06116019?

NCT06116019 is sponsored by Charite University, Berlin, Germany.

What drugs are being tested in NCT06116019?

Interventions in NCT06116019: Online adaptive radiation therapy.

What condition does NCT06116019 study?

NCT06116019 studies Prostate Cancer, Head and Neck Cancer, NSCLC, SCLC, Esophageal Cancer, Bladder Cancer, Rectum Cancer, Cervix Cancer, Other Carcinoma.

Is NCT06116019 still recruiting?

NCT06116019 is currently recruiting now. Last updated 3 November 2023.

Last reviewed 2023-11-03 · How we verify

NCT06116019: ART-02

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)

Recruiting now Last updated 3 November 2023

What this trial tests

trial testing Online adaptive radiation therapy in Prostate Cancer in 649 participants. Currently enrolling.

Timeline

11 October 2023

Primary endpoint
9 October 2026

9 October 2027

Quick facts

Lead sponsor	Charite University, Berlin, Germany
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	649
Start date	11 October 2023
Primary completion	9 October 2026
Estimated completion	9 October 2027
Sites	1 location across Germany

Drugs / interventions tested

Online adaptive radiation therapy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Head and Neck Cancer — all drugs for Head and Neck Cancer →
NSCLC — all drugs for NSCLC →
SCLC — all drugs for SCLC →

Sponsor

Charite University, Berlin, Germany

Who can join

18 and older, any sex, with Prostate Cancer or Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (ART) using the Varian/SHS ETHOS treatment system. In this study, radiation treatment plans are dynamically adjusted on a daily basis over several weeks of therapy to account for anatomical shifts in either the tumour or adjacent normal tissue - a capability that has been difficult to achieve due to technical limitations. With the ETHOS accelerator, such real-time adjustments can be made based on cone beam computed tomography (CBCT). This is a prospective observational study with the primary objective of investigating the feasibility and acceptability of performing ART with ETHOS for different tumour entities. The study will also evaluate the feasibility of integrating multi-parametric data sets into the ART workflow, such as standardised electronic feedback on treatment toxicity from both patients (ePROMS) and physicians (ePRT).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Optimizing Workflow for Cone Beam Computed Tomography-Based Online Adaptive Radiation Therapy Toward Reduced Physician Involvement.
Kalinauskaite G, Künzel LA, Kluge A, Rubarth K, et al · · 2025 · cited 4× · PMID 40927651 · DOI 10.1016/j.adro.2025.101874
Prospective controlled study comparing patient-reported outcomes after daily online adaptive radiotherapy or conventional IGRT in patients with prostate cancer.
Kalinauskaite G, Künzel LA, Rubarth K, Nguyen T, et al · · 2026 · PMID 41492405 · DOI 10.1016/j.ctro.2025.101092

Verify or expand the search:

Other trials of Online adaptive radiation therapy

Trials testing the same drug.

NCT05911789 — Online Adaptive Radiation Therapy for Rectal Cancer · Phase 1, PHASE2 · unknown

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Charite University, Berlin, Germany trials

Trials by the same sponsor.

NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06116019 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
Last refreshed: 3 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06116019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing